Iverson Genetics has selected GenMark Diagnostics' eSensor Warfarin Sensitivity Test for use in its new pivotal clinical study, the Warfarin trial (Warfarin Adverse event Reduction For Adults Receiving genetic testing at therapy Initiation).

The trial will evaluate the value of genetic testing on reducing adverse events associated with Warfarin therapy.

GenMark, a provider of automated, multiplex molecular diagnostic testing systems, said that the eligible patients in the clinical study will be reimbursed by the Centers for Medicare and Medicaid Services (CMS) through a temporary code developed to enable the implementation of pharmacogenomic testing under the Coverage with Evidence Development (CED) provision in the Social Security Act.

Iverson Genetics CEO Dean Sproles said that they selected GenMark Diagnostics’ technology for its ability to provide accurate and reliable results and the XT-8 allows fast processing and simple interpretation of patient results.

GenMark Diagnostics CEO Christopher Gleeson said that they are pleased to have their Warfarin Sensitivity Test selected for inclusion in this clinical study and they believe that the ease of use of their eSensor XT-8 system provides a clear choice for diagnostic laboratories and research centers.

Seattle-based Iverson Genetics provides physicians with actionable genetic information to optimize clinical decision-making and patient care.